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Abstract 
B-crystallin (BC) is a small heat shock protein.  Mutations in the BC gene are 
linked to -crystallinopathy, a hereditary myopathy histologically characterized by 
intracellular accumulation of protein aggregates.  The disease-causing R120G BC 
mutant, harboring an arginine-to-glycine replacement at position 120, is an aggregate-
prone protein.  We previously showed that the R120G mutant’s aggregation in HeLa 
cells was prevented by enforced expression of BC on the endoplasmic reticulum (ER).  
To elucidate the molecular nature of the preventive effect on the R120G mutant, we 
isolated proteins binding to ER-anchored BC (TMBC).  The ER transmembrane 
CLN6 protein was identified as a TMBC's binder.  CLN6 knockdown in HeLa cells 
attenuated TMBC's anti-aggregate activity against the R120G mutant.  Conversely, 
CLN6 overexpression enhanced the activity, indicating that CLN6 operates as a 
downstream effector of TMBC.  CLN6 physically interacted with the R120G mutant, 
and repressed its aggregation in HeLa cells even when TMBC was not co-expressed.  
Furthermore, CLN6’s antagonizing effect on the R120G mutant was compromised upon 
treatment with a lysosomal inhibitor, suggesting CLN6 requires the intact autophagy-
2 
lysosome system to prevent the R120G mutant from aggregating.  We hence conclude 
that CLN6 is not only a molecular entity of the anti-aggregate activity conferred by the 
ER manipulation using TMBC, but also serves as a potential target of therapeutic 
interventions. 
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1. Introduction
BC is a member of the small heat shock protein family.  Mutations in the BC gene 
are linked to -crystallinopathy, an autosomal dominantly inherited myopathy [1].  
The pathogenesis of this disease is poorly understood and there is no curative therapy 
available.  Histologically, -crystallinopathy is characterized by accumulation of 
aberrant protein aggregates in cardiomyocytes and skeletal myocytes.  Formation of 
protein aggregates is closely associated with a wide array of degenerative 
neuromuscular disorders, including amyotrophic lateral sclerosis, Alzheimer's disease 
and -crystallinopathy [2–5].  Molecular mechanisms underlying aggregate 
accumulation have thus been investigated and therapeutic interventions with which to 
antagonize aggregate-prone proteins have been required to be established.  The 
disease-causing R120G BC mutant is one of those proteins with aggregation 
propensities, and aggregates when transfected into non-muscle cell lines [6].  We 
previously showed that aggregation of the R120G mutant in HeLa cells was prevented 
by co-expressed TMBC, and hypothesized that some proteins situated on the ER were 
manipulated via interactions with TMBC, thereby exerting their anti-aggregate activity 
toward the R120G mutant [7].  To reveal the molecular basis of this ER-based 
antagonistic action on the aggregate-prone mutant, we purified TMBC-binding 
proteins.  Here we identified CLN6, an ER transmembrane protein linked to neuronal 
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ceroid lipofuscinosis [8–10], as an effector molecule operating downstream of TMBC.  
Based on our results, we propose that CLN6 has anti-aggregate activity and would be a 
promising target in developing therapeutic strategies for protein aggregation diseases. 
 
2. Materials and methods  
2.1. Expression vectors and small interfering RNAs 
The construction of the following expression vectors was described previously [11,12]: 
pEGFP-N1-R120G BC mutant (R120G-EGFP), pcDNA4/myc-BC (WTBC), and 
pcDNA4/myc-TMBC (TMBC).  The DNA fragment encoding human CLN6 was 
PCR-generated using the following primers: 5’-
GGCAAGCTTCACCATGGAGGCGACGCGGAGGCGGC-3’ and 5’-
GCCGTCGACGAATTCCAGTGCCGACTGCTGACGTG-3’.  The template was 
cDNA synthesized with the GoScript Reverse Transcription System (Promega) 
employing RNA isolated from HeLa cells.  The PCR product was digested with 
HindIII/SalI, and then cloned in frame into the HindIII/SalI-digested pEGFP-N1vector 
(TAKARA Bio).  The resulting pEGFP-N1-CLN6 (CLN6-EGFP) expression construct 
was digested with HindIII/EcoRI to yield the DNA fragment corresponding to full-
length CLN6.  This fragment was then cloned in frame into the HindIII/EcoRI-
digested pcDNA4/myc-His vector (Invitrogen), generating pcDNA4/myc-CLN6 
(CLN6).  All the constructs were subjected to DNA sequencing.  To knock down 
CLN6, two different siRNA duplexes (Sigma-Aldrich) as below were individually 
transfected into HeLa cells: siCLN6a (5′-CUCUCGAGUGGUUUCCACUTT-3′ and 5′-
AGUGGAAACCACUCGAGAGTT-3′) and siCLN6b (5′-
CCCUCUUGCUUGUGGCGCUTT-3′ and 5′-AGCGCCACAAGCAAGAGGGTT-3′).  
The siRNA duplex against ATG5 (siATG5) was described previously [12]. 
 
2.2. Cell culture and transfection 
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HeLa cells were maintained in MEM (nacalai tesque, Japan) supplemented with 10% 
fetal bovine serum at 37 °C in a humidified cell culture incubator with 5% CO2.  For 
transfection, the cells were seeded at 1.5 x 104 cells per well onto 24-well plates or 35-
mm glass bottom dishes 20 h prior to transfection.  The cells in each well were 
transfected with single (0.4 µg) or two different (0.2 µg each) expression constructs 
mixed with 1.2 µl of PEI “Max” (Polysciences), or 0.34 µg of siRNA mixed with 2 µl 
of the X-tremeGENE siRNA transfection reagent (Roche).  
 
2.3. Reverse transcription polymerase chain reaction analysis 
Reverse transcription polymerase chain reaction (RT-PCR) was performed as described 
previously [13].  Primers used were as follows: 5′-GCATTGCTGACAGGATGCAG-
3′ and 5′-CCTGCTTGCTGATCCACATC-3′ for β-actin, 5′-
GCATGGCTCTGTGAGCGCTGATGAGGCTG-3′ and 5′-
GCAGAATTCGAGTCACCCACCAGGTGGATGCTG-3′ for CLN6. 
 
2.4. Antibodies 
Antibodies used are as follows: Actin (diluted 1:200, Santa Cruz Biotech, C-2, sc-
8432), ATG5 (diluted 1:1000, Cell Signaling, #2630), CLN6 (diluted 1:200, abcam, 
ab82786), LC3-I/II (diluted 1:500, Cell Signaling, #12741), c-Myc (diluted 1:200, Santa 
Cruz Biotech, 9E10, sc-40), GFP (diluted 1:1000, MBL, #598), and horse radish 
peroxidase (HRP)-conjugated antibodies (diluted 1:3000, rabbit anti-mouse IgG and 
goat anti-rabbit IgG, both from DAKO).  
 
2.5. Immunoblot analysis 
At 16 h post-transfection, HeLa cells were solubilized in RIPA lysis buffer (100 mM 
Tris (pH 7.5), 150 mM NaCl, 2 mM EDTA, 1% TrironX-100, 1% DOC and 0.1% SDS 
plus protease inhibitor cocktail) and incubated on ice for 30 min, then centrifuged at 
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14,800 rpm for 10 minutes.  Soluble fraction was collected, mixed with 2X Laemmli 
buffer, boiled, resolved by SDS–PAGE, and electrotransferred onto polyvinylidene 
difluoride membranes.  The membranes were then incubated with primary and 
secondary antibodies described in 2.4 Antibodies.  HRP on the membrane was 
detected using the ImmunoStar luminescence solution (Wako Pure Chemical Industries, 
Japan) according to the manufacturer’s instruction. 
 
2.6. Immunoprecipitation assay 
At 16 h post-transfection, HeLa cells were solubilized in lysis buffer (50 mM Tris (pH 
8.0) and 150 mM NaCl with 1% NP-40 plus protease inhibitor cocktail).  The lysates 
were incubated with antibodies against myc or GFP overnight at 4 °C, subjected to 
incubation with protein A-Sepharose (GE Healthcare Life Sciences) for another hour.  
Subsequently, the immunoprecipitates were resolved by SDS–PAGE and 
electrotransferred onto polyvinylidene difluoride membranes for immunoblotting with 
specific antibodies. 
 
2.7. Mass spectrometric analysis 
Myc immunoprecipitates derived from 1.5 x 104 transfected HeLa cells were separated 
by SDS-PAGE.  The gel was stained using Pierce® Silver Stain for Mass 
Spectrometry (Thermo Fisher Scientific) according to the manufacture’s protocol.  The 
bands selected as potential binding partners of TMBC were excised and in-gel 
digested with trypsin according to a previously published method [14].  The digested 
peptides were subjected to liquid chromatography-mass spectrometry/mass 
spectrometry (LC-MS/MS) analysis.  Nano liquid chromatography of these peptides 
and the mass spectrometric analysis were performed with the UltiMate 3000 RSLCnano 
system (Thermo Fisher Scientific) and an Orbitrap Elite mass spectrometer (Thermo 
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Fisher Scientific), respectively.  The data was analyzed with Mascot (Matrix Science) 
MS/MS Ion Search to assign the obtained peptides to the NCBI database. 
2.8. Measurement of aggregate positivity 
At 16 h post-transfection, live HeLa cells expressing EGFP-tagged R120G BC mutant 
were subjected to confocal microscopic analysis.  EGFP images were acquired using a 
Zeiss LSM-700 confocal microscope with 20x/0.75 NA dry objective, and analyzed 
with the ZEN Lite software (Carl Zeiss Inc.).  Based on the images, the percentage of 
cells with aggregates in EGFP-positive cells was calculated.  At least 800 cells were 
analyzed for each condition in every assay. 
 
2.9. Statistical analysis 
All data is expressed as means ± S.E.M.  The data was accumulated under each 
condition from at least seven independent experiments.  For non-parametric all-pairs 
multiple comparisons, Steel–Dwass test was used. 
 
3. Results 
3.1 CLN6 was identified as a binding partner of TMBC 
TMBC prevented the R120G mutant from aggregating, while wild-type BC 
(WTBC), which is scattered throughout the cytoplasm, did not.  The finding 
prompted us to reason that proteins possessing anti-aggregate activity are situated on the 
ER, cooperating with TMBC.  To elucidate the molecular nature of TMBC’s 
preventive effect on aggregate formation, we purified and mass spectrometrically 
analyzed proteins that specifically bound to TMBC (Suppl. Fig. 1).  One of the 
identified proteins was the ER-resident transmembrane CLN6 protein, variants of which 
are linked to neuronal ceroid lipofuscinosis, classified as a lysosomal storage disease.  
To validate CLN6’s interaction with TMBC, HeLa cells were co-transfected with an 
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EGFP-tagged version of CLN6 plus either myc-tagged TMBC or WTBC, subjected 
to co-immunoprecipitation assays.  CLN6 co-immunoprecipitated with TMBC, but 
not with WTBC (Fig. 1), further supporting specific physical interactions between 
CLN6 and TMBC. 
 
3.2 CLN6 was a downstream effector of TMBC 
The demonstrated physical interactions led us to postulate that CLN6 operates 
downstream of TMBC.  To explore this possibility, we investigated if CLN6 
knockdown impairs TMBC’s anti-aggregate activity toward the R120G mutant.  Two 
different siRNA duplexes (siCLN6a and siCLN6b) were separately used to silence the 
CLN6 gene, and depletion of CLN6 in HeLa cells was verified at both transcript and 
protein levels (Fig. 2A, B).  The siRNA-transfected cells were subsequently co-
transfected with the R120G mutant plus TMBC, subjected to microscopic analysis 
(Fig. 2C).  Aggregate positivity in CLN6-depleted cells was ~25% higher than that in 
CLN6-sufficient counterparts (Fig. 2D), indicating that TMBC’s preventive effect on 
the R120G mutant is mediated, at least in part, by CLN6. 
 
3.3 CLN6 prevented aggregate formation without the guidance of TMBC 
We further explored whether CLN6 exerts anti-aggregate activity against the R120G 
mutant even without cooperation of TMBC.  When co-transfected with the R120G 
mutant into HeLa cells, CLN6 mitigated the R120G mutant-mediated aggregate 
formation to a similar extent as TMBC (Fig. 3A, B).  In contrast, CLN6 knockdown 
in HeLa cells elevated aggregate positivity by approximately 25%, compared with the 
control knockdown (Fig. 3C).  Given that myc-tagged CLN6 co-immunoprecipitated 
with the R120G mutant tagged with EGFP (Fig. 3D), we concluded that endogenous 
CLN6 serves to prevent the mutant from aggregating in a TMBC-independent manner 
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as well, which would be underpinned by physical interactions between CLN6 and the 
mutant.  
 
3.4 CLN6 required the autophagy-lysosome system to counter the R120G mutant  
Integrity of the autophagy-lysosome system is essential to prevent aggregate 
accumulation [15,16].  We thus investigated if inhibitors of the proteolytic system 
affect CLN6’s anti-aggregate activity toward the R120G mutant.  Bafilomycin A1, a 
lysosomal inhibitor, elevated the aggregate positivity in a dose-dependent manner, 
whereas the MG132 proteasome inhibitor did not significantly affect the aggregate 
formation (Fig. 4A), indicating CLN6 antagonizes the R120G mutant by utilizing the 
autophagy-lysosome pathway.  We further assessed the autophagy dependency of 
CLN6 using siRNA against ATG5, a protein involved in earlier steps of autophagy [17].  
ATG5-depleted HeLa cells and their counterparts displayed comparable aggregate 
positivity following co-transfection with CLN6 plus the R120G mutant (Fig. 4B, C).  
Like TMBC, CLN6 appeared to employ an ATG5-independent autophagic pathway to 
counter the mutant when an ATG5-dependent pathway is not available.  Of note, 
neither overexpressed CLN6 nor TMBC elevated LC3-II protein levels, one of the 
indicators of autophagic flux [18] (Fig. 4D).  Rather than upregulating the autophagy-
lysosome system, CLN6 was suggested to protect the system from detrimental effects of 
aggregate-prone proteins.  
 
4. Discussion 
We previously demonstrated that overexpression of TMBC, but not of WTBC, 
prevents aggregation of the disease-causing R120G BC mutant, proposing that some 
proteins situated on the ER are manipulated by TMBC and help repress aggregate 
formation.  Here we identified CLN6 as a binding partner and downstream effector of 
TMBC.  Although evenly distributed across the cytoplasm, WTBC did not bind to 
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CLN6, implying that there are as-yet-unidentified obstacles surrounding the ER 
membrane that hamper WTBC's access to CLN6.  When tethered to the ER 
membrane, BC is most likely to override such obstacles and readily reach CLN6.  
Considering that TMBC bound to the R120G mutant, the mutant would be brought 
into the proximity CLN6 primed by TMBC to exhibit its anti-aggregate activity.  
Alternatively, TMBC could derepress rather than stimulate CLN6.  There might be 
proteins negatively regulating CLN6 through physical interactions.  TMBC would 
bind to and dissociate those potentially inhibitory proteins from CLN6, unleashing the 
anti-aggregate activity of CLN6.  This scenario could explain why overexpressed 
CLN6 prevented aggregation of the R120G mutant without assistance from TMBC.  
In this case, CLN6 would outnumber inhibitory proteins.  As a result, a considerable 
amount of CLN6 can escape the restraint and readily act on the R120G mutant.  Either 
way, formation of a multi-protein complex including CLN6 and the R120G mutant as 
its component is most likely to be the driving force behind the observed anti-aggregate 
activity. 
Integrity of the autophagy-lysosome system was required for CLN6 to antagonize the 
R120G mutant.  CLN6, however, appeared not to upregulate autophagy, given that 
overexpression of CLN6 had no appreciable impacts on LC3-II protein levels.  We 
hence reasoned that CLN6, rather than enhancing autophagy, just nullify the R120G 
mutant’s aggregate-prone properties.  The mutant might be structurally constrained by 
CLN6, remaining as an aggregate precursor not detrimental to the autophagy-lysosome 
machinery.  ATG5-dependent and/or -independent autophagic pathways would likely 
be kept functional and engaged in clearance of the resulting aggregate precursors. 
Mutations in the CLN6 gene are linked to variant late-infantile neuronal ceroid 
lipofuscinosis (vLINCL) [10,19], classified as a lysosomal storage disorder.  
Numerous aggregates positive for the autophagy-related protein p62 have been found in 
brains of the nclf mouse model of vLINCL [20], where the CLN6 protein is prematurely 
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truncated.  This is consistent with our findings that CLN6 knockdown augmented the 
R120G mutant-mediated aggregate formation.  CLN6 is most likely to antagonize 
aggregate-prone proteins in an individual mouse as well.  In this regard, quantitatively 
upregulating CLN6 would thus be therapeutically effective for vLINCL, provided that 
accumulation of the p62-aggregate is central to the pathogenesis of vLINCL. 
We previously demonstrated that manipulation of the microenvironment surrounding 
the ER membrane would likely be beneficial for developing therapeutic strategies 
against -crystallinopathy, characterized by intracellular accumulation of protein 
aggregates.  Here, we not only identified CLN6 as a target of the ER manipulation, but 
also have given novel etiological insights into how defects in the ER-resident CLN6 
protein are associated with alterations in an anatomically distinct compartment of the 
lysosome. 
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Figure legends 
 
Figure 1.  Specific interactions between TMBC and CLN6. 
HeLa cells were co-transfected with a vector expressing EGFP-tagged CLN6 (CLN6) in 
combination with a vector encoding myc-tagged wild-type (WTBC) or ER-anchored 
(TMBC) BC.  Whole cell lysates (Input) and the GFP immunoprecipitates (IP: 
GFP), both derived from the co-transfected cells, were immunoblotted with the 
indicated antibodies. 
 
Figure 2.  CLN6 knockdown attenuated TMBC’s anti-aggregate activity toward the 
R120G mutant. 
(A)  HeLa cells were transfected with either siRNA against CLN6 (siCLN6a, siCLN6b) 
or a scrambled control siRNA (Sc).  At 24 h post-transfection, transcript levels of 
CLN6 and Act-b were examined by RT-PCR. 
(B)  Protein levels of CLN6 and actin in HeLa cells transfected with the indicated 
siRNAs were examined at 40 h post-transfection by immunoblotting. 
(C)  HeLa cells were sequentially transfected with the indicated siRNAs, and with the 
EGFP-tagged R120G mutant (R120G) plus TMBC.  After 16 h, the cells were 
imaged with a fluorescence microscope.  Scale bars: 20m  
(D)  Based on EGFP images in (C), the percentage of cells with aggregates in EGFP-
positive cells was calculated.  The data is expressed as means ± SEM of seven 
independent experiments.  *p < 0.05.  At least 800 cells were analyzed for each 
condition in every assay. 
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Figure 3.  CLN6 prevented aggregate formation independently of TMBC. 
(A) Whole cell lysates from HeLa cells co-transfected with the EGFP-tagged R120G
mutant (R120G) plus either myc-tagged WTBC, TMBC or CLN6 were
immunoblotted with antibodies against myc or actin.
(B) The cells were co-transfected as in (A), subjected to microscopic analysis.
Shown is the percentage of cells with aggregates in EGFP-positive cells, calculated
in the same way as Fig. 2D.  The data is expressed as means ± SEM of seven
independent experiments.  *p < 0.01.  At least 800 cells were analyzed for each
condition in every assay.
(C) Shown is the percentage of cells with aggregates in EGFP-positive cells.  Cells
were sequentially transfected with the indicated siRNAs and the R120G mutant
under the same experimental condition as that in Fig. 2C.  The data is expressed as
means ± SEM of seven independent experiments.  *p < 0.01.  At least 800 cells
were analyzed for each condition in every assay.
(D) HeLa cells were co-transfected with the myc-tagged CLN6 (CLN6) plus either
EGFP or the R120G mutant tagged with EGFP (R120G-EGFP).  Whole cell lysates
(Input) and the myc immunoprecipitates (IP: Myc) were derived from the co-
transfected cells, subjected to immunoblotting with the indicated antibodies.
Figure 4.  The autophagy-lysosome system was required for CLN6’s anti-aggregate 
activity.  
(A) The EGFP-tagged R120G mutant and the myc-tagged CLN6 were co-expressed in
HeLa cells.  At 16 h post-transfection, the cells were treated with either
Bafilomycin A1 or MG132, incubated for another 3 h, and then microscopically
analyzed for aggregate positivity as in Fig. 2D.  The data is expressed as means ±
SEM of six independent experiments.  *p < 0.01.  At least 800 cells were
analyzed for each condition in every assay.
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(B) Whole cell lysates of HeLa cells transfected with either siRNA against ATG5
(siATG5) or a scrambled control siRNA (Sc) were immunoblotted with the indicated
antibodies.
(C) Shown is the percentage of cells with aggregates in EGFP-positive cells.  Cells
were sequentially transfected the indicated siRNAs and the combinations of
expression constructs, subjected to microscopic analysis for aggregate positivity as
in Fig. 2C.  The data is expressed as means ± SEM of seven independent
experiments.  **p < 0.01, *p < 0.05.  At least 800 cells were analyzed for each
condition in every assay.
(D) Whole cell lysates of HeLa cells co-transfected with the indicated combinations of
expression constructs were analyzed by immunoblotting with antibodies against
LC3-I/II or actin.
Supplementary Figure 1.  Detection of proteins specifically binding to TMBC.  
The myc immunoprecipitates derived from HeLa cells transfected with expression 
constructs encoding either myc-tagged TMBC or WTBC, or with the control empty 
vector were separated by SDS-PAGE, visualized by silver staining.  Protein bands 
indicated with arrows were excised, subjected to mass spectrometric analysis. 
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